<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815528</url>
  </required_header>
  <id_info>
    <org_study_id>Cat-Ovar_2011</org_study_id>
    <nct_id>NCT01815528</nct_id>
  </id_info>
  <brief_title>Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer</brief_title>
  <official_title>Single -Arm, Multicenter Phase-II Trial for Catumaxomab and Chemotherapy in Patients With Recurrent Ovarian Cancer to Investigate the Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy Regimes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JSehouli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single -arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with&#xD;
      recurrent ovarian cancer to investigate the feasibility and clinical activity of initial&#xD;
      intraperitoneal catumaxomab followed by chemotherapy regimes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of close sequential combination of catumaxomab and established chemotherapy regimens</measure>
    <time_frame>Approximately 5 months after start of treatment per patient</time_frame>
    <description>Feasibility of close sequential combination of catumaxomab and established chemotherapy regimens defined by rate of patients with at least 4 chemotherapy cycles following 4 applications of catumaxomab within 20 days as described in the scope of this clinical trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and severity of adverse events as a measure of safety and tolerability</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Overall safety evaluation, including cytokine related toxicities (safety score catumaxomab&#xD;
number and severity of adverse events&#xD;
number of patients with AEs&#xD;
occurrence of cytokine release related symptoms&#xD;
hospitalization frequency and duration&#xD;
changes in clinically relevant laboratory values (hematology, clinical chemistry, coagulation, and urinalysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who can receive all 4 applications of catumaxomab within 20 days and who are able and committed to receive further mono chemotherapy</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Percentage of patients who can receive all 4 applications of catumaxomab within 20 days and who are able and committed to receive further mono chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who can start chemotherapy after a maximum of 4-7 days after last catumaxomab application</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Percentage of patients who can start chemotherapy after a maximum of 4-7 days after last catumaxomab application</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with no signs of malignant ascites at time of progression or change of therapeutic strategy</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Percentage of patients with no signs of malignant ascites at time of progression or change of therapeutic strategy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puncture-free interval (defined as paracentesis-free interval after last catumaxomab application/ removal of catheter)</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Puncture-free interval (defined as paracentesis-free interval after last catumaxomab application/ removal of catheter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP) according to RECIST and/or CA-125 response rate</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Time to progression (TTP) according to RECIST and/or CA-125 response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) defined as patients with complete or partial response and duration of response (according to RECIST and/or CA-125 response)</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Overall response rate (ORR) and duration of response (according to RECIST and/or CA-125 response) of second or third or fourth line chemotherapy and compare with historical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess treatment free interval to subsequent therapy (defined as duration of the interval between last chemotherapy application and start of next chemotherapy</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>To assess treatment free interval to subsequent therapy (defined as duration of the interval between last chemotherapy application and start of next chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess PFS according to RECIST and/or CA-125 response rate, OS</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>To assess PFS according to RECIST and/or CA-125 response rate, OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess quality of life over time as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>To assess quality of life over time as defined by EORTC-QLQ C 30 and Ovar 28 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential predictive clinical factors for response to catumaxomab</measure>
    <time_frame>Approximately 2.5 years after start of study</time_frame>
    <description>Analysis of potential predictive clinical factors for response to catumaxomab (e.g. amount of ascites, histology, relative lymphocyte count)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Recurrent Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Catumaxomab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catumaxomab treatment followed by an established chemotherapy regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Catumaxomab</intervention_name>
    <description>Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:&#xD;
10 µg on day 0&#xD;
20 µg on day 3&#xD;
50 µg on day 7&#xD;
150 µg on day 10</description>
    <arm_group_label>Catumaxomab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed epithelial ovarian cancer, primary&#xD;
             peritoneal carcinomatosis or fallopian tube cancer&#xD;
&#xD;
          -  Recurrent ovarian cancer disease&#xD;
&#xD;
          -  Signs for progression either measurable disease according to RECIST or CA 125 increase&#xD;
             according the GCIG-criteria or clinical symptoms of tumor progression according to&#xD;
             RECIST&#xD;
&#xD;
          -  Radiologically and cytologically confirmed malignant ascites possible to puncture&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  ECOG performance status at least 1&#xD;
&#xD;
          -  No prior operation or, in case of prior operation, the patient must be recovered&#xD;
             therefrom. The operation must be performed at least 4 weeks prior to start of study&#xD;
             drug&#xD;
&#xD;
          -  Capable of understanding the purposes and risks of the study, willing and able to&#xD;
             participate in the study, and written informed consent&#xD;
&#xD;
          -  Non-childbearing potential or negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known brain metastases&#xD;
&#xD;
          -  Concomitant cancer, chemo- or radiotherapy (except for local radiation therapy for&#xD;
             bone marrow metastases)&#xD;
&#xD;
          -  Any investigational product within 2 weeks prior to first administration of&#xD;
             catumaxomab&#xD;
&#xD;
          -  In cases of previous exposure to investigational product, cancer-, chemo-, immune- or&#xD;
             radiotherapy (except for local radiation therapy for bone marrow metastasis):&#xD;
&#xD;
        not sufficiently recovered from previous treatment (toxicity present) based on adequate&#xD;
        laboratory values and general status according to other in-/exclusion criteria (i.e. this&#xD;
        might be less than 1 or 2 weeks after a weekly or bi-weekly scheduled previous therapy&#xD;
        regimen)&#xD;
&#xD;
          -  Patients must not have been exposed to nitrosoureas or mitomycin C within 6 weeks&#xD;
             prior the first infusion of catumaxomab&#xD;
&#xD;
          -  Abnormal organ or bone marrow function&#xD;
&#xD;
          -  Use of immune-suppressive agents for the past 4 weeks prior to first administration of&#xD;
             catumaxomab. For regular use of systemic corticosteroids patients should only be&#xD;
             included after stepwise discontinuation to be free of steroids for a minimum of 5 days&#xD;
             prior to study entry&#xD;
&#xD;
          -  Any known active and chronic infection&#xD;
&#xD;
          -  Known HIV infection and / or hepatitis B virus or hepatitis C virus&#xD;
&#xD;
          -  Any other concurrent disease or medical conditions that are deemed to interfere with&#xD;
             the conduct of the study as judged by the investigator&#xD;
&#xD;
          -  Known or suspected hypersensitivity to catumaxomab and its analogues in general or to&#xD;
             murine proteins (from rat or mouse)&#xD;
&#xD;
          -  Known or suspected hypersensitivity to PLD, topotecan, paclitaxel, gemcitabine or&#xD;
             their excipients.&#xD;
&#xD;
          -  Patients with congestive heart failure New York Heart Association (NYHA) Class III and&#xD;
             IV. Cardiac arrhythmias (except atrioventricular block type I and II, atrial&#xD;
             fibrillation/flutter bundle brunch block)or other signs and symptoms of relevant&#xD;
             cardiovascular disease&#xD;
&#xD;
          -  Body mass index (BMI) &lt; 17 (assessment after ascites drainage)&#xD;
&#xD;
          -  Inadequate respiratory function in the opinion of the investigator&#xD;
&#xD;
          -  Presence of complete bowel obstruction&#xD;
&#xD;
          -  Patients with substance abuse, medical or psychological or social conditions which the&#xD;
             investigator believes would preclude compliance with the study requirements.&#xD;
&#xD;
          -  Unwilling or unable to follow protocol requirements&#xD;
&#xD;
          -  Participation in another clinical study with experimental therapy within 14 days&#xD;
             before start of treatment&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Subjects housed in an institution on official or legal orders&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>March 14, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <last_update_submitted>February 17, 2015</last_update_submitted>
  <last_update_submitted_qc>February 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>JSehouli</investigator_full_name>
    <investigator_title>Prof. Dr. med. Jalid Sehouli</investigator_title>
  </responsible_party>
  <keyword>recurrent epithelial ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Catumaxomab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

